Skip to main content
OpenTrials
Completed

NCT Number: NCT00144560

Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)

This is an open-label, clinical pharmacology study to investigate drug-drug interaction in patients with RA.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are diagnosed with RA according to the 1987 American College of Rheumatology (ACR) classification criteria
  • Patients who contracted RA at least 6 months prior

Exclusion criteria

  • Patients with Class IV Steinbrocker functional impairment at enrollment.
  • Patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept and have been receiving treatment with leflunomide, within 12 weeks before initiation of treatment with the probe drug

Treatment and study plan

MRA(Tocilizumab)

Drug

Primary outcomes

  1. 20% improvement based on the ACR criteria compared with the baseline value.

    Time frame: throughout study

Secondary outcomes

  1. Time courses taken from baseline values for DAS28, for ACR20%, 50%, and 70% improvement, and for each ACR core set variable.

    Time frame: Week 0,Week 1, Week 2

Sponsors and collaborators

Lead sponsor

Chugai Pharmaceutical

Industry

Registry information

Official study title

An Open-Label, Clinical Pharmacology Study to Investigate Drug-Drug Interaction in Patients With RA

Important dates

Study start
2005
Primary completion
2005
Study completion
2005
First posted
Sep 5, 2005
Registry last updated
Dec 15, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.